


Docket No: Advcl01A-C1
Applicant: Graham, et al.
Filed: 10/16/2001
Serial No: 09/978,464

1/15/2002



For Submission to the USPTO:

1. Response to Notice to File Missing Parts Trans.
2. executed declaration & power of attorney
3. basic filing fee: \$740.00
4. additional claims fee: \$840.00
5. missing parts surcharge: \$130.00
6. substitute drawings
7. abstract
8. sequence listing on disk
9. sequence listing statement





UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/978,464 | 10/16/2001 | Frank L. Graham | ADVEC101A-C1 |

29847
VAN DYKE & ASSOCIATES, P.A.
1630 HILLCREST STREET
ORLANDO, FL 32803

CONFIRMATION NO. 5099

FORMALITIES LETTER



OC000000007075530

Date Mailed: 11/15/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 740 to complete the basic filing fee for a non-small entity. If appropriate, applicant may make a written assertion of entitlement to small entity status and pay the small entity filing fee (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$840.
 - \$252 for 14 total claims over 20.
 - \$588 for 7 independent claims over 3.
- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(f) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 1710.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer-readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

1630 Hillcrest Street
Orlando, Florida 32803
USA

**Van Dyke
&
Associates, PA**
INTELLECTUAL PROPERTY LAW

Phone: (407) 228-0328
Fax: (407) 228-0329
info@patentinternational.com
www.patentinternational.com

FACSIMILE COVER SHEET

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

TO : USPTO
FAX No. : 703-746-9195
No of PAGES : 45 (including cover sheet)
FROM : Van Dyke & Associates, P.A.
DATE : May 9, 2002
RE: : Serial No: 09/978,464
Our Docket No: AdVcc101A-C1

VIA FACSIMILE ONLY


To Whom It May Concern:

Please see the attached as requested in the "Request for Substitute Papers" mailed on April 25, 2002. The Request has been signed and dated clarifying that this facsimile submission is complete and accurate as originally filed.

Applicant also provides herewith a copy of an executed Revocation & New Power of Attorney for this case, which is the last page of this facsimile.

If you have any questions regarding this correspondence, please feel free to contact me.

Regards,



Timothy H. Van Dyke, Reg. No. 43218
Van Dyke & Associates, P.A.
TVD/mkk
Attachments

If you do not receive all pages or if any portion of this transmission is not legible, call the sender at (407) 228-0328.




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| Application Number | Filing Date | First Named Applicant | Atty. Docket No. |
|--------------------|-------------|-----------------------|------------------|
| 09/978,464 | 10/16/2001 | Graham, Frank | ADVEC101A-C1 |

29847

VAN DYKE & ASSOCIATES, P.A.
1630 HILLCREST STREET
ORLANDO FL 32803



Date Mailed: 04/25/2002

Title: Enhanced system for construction of adenovirus vectors

Request for Substitute Papers

The papers filed on 02/11/02 (certificate of mailing dated 01/15/02) are no longer in condition to become part of the permanent records of the United States Patent and Trademark Office (USPTO) for this application (37 CFR 1.52(a)) due to the United States Postal Service sanitization process.

The USPTO requests that applicant provide a copy of the above-identified papers (except for any U.S. or foreign patent documents submitted with the above-identified papers) with a statement that such copy is a complete and accurate copy of the above-identified papers (signing and returning a copy of this notice will provide such a statement). The reply to this letter should be submitted to the USPTO by facsimile at the number indicated [REDACTED] 703-746-9195

Alternatively, the reply to this letter may be hand-carried to the Customer Service Window located in Room 1B03 of Crystal Plaza Building 2, Arlington, Virginia, 22202.

The USPTO strongly prefers that the reply to this letter be submitted by facsimile. However, if applicant cannot submit the reply to this letter by facsimile (or hand-delivery), the reply may be mailed to: Box Duplicate OIPE, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202-2327.

This letter is not a notice under 37 CFR 1.251. However, failure to timely replay to this notice within two (2) weeks of the date of receipt of this letter may result in the USPTO issuing a notice under 37 CFR 1.251. A copy of this notice should be included with the reply.

The enclosed papers are a complete and accurate copy of the above-identified papers.

Name: Timothy A. Van Dyke Registration No.: 43,218Signature: [Signature] Date: 5-9-02

Date received 5/29/02
Docketed 5/30/02 By [Signature]
Timely response due 5/9/02
Last date to file response 5/9/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEApplicant(s): Graham *et al.*

Application No.: 09/978,464

Filed: 10/16/2001

Title: Enhanced System for Construction of
Adenovirus Vectors

Attorney Docket No.: ADVEC101A-C1

Group Art Unit: 1636

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Assistant Commissioner for Patents

Washington, D.C. 20231

Attention: Box Missing Parts

Sir: This is in response to a Notice to File Missing Parts of Application under 37 CFR 1.53(b). Enclosed is a copy of said Notice and the following documents and fees to complete the filing requirements of the above-identified application.

- (X) Copy of the executed Declaration and Power of Attorney from parent application serial no. 09/415,899.
- (X) Statutory basic filing fee \$740.00. (X) Utility () Design
- (X) Additional claim fees of \$840.00 (\$252.00 for 14 total claims over 20 and \$588.00 for 7 independent claims over 3).
- (X) Missing Parts Surcharge of \$130.00.
- (X) Substitute drawings in compliance with 37 C.F. R. 1.84.
- (X) Abstract as required under 37 C.F.R. 1.72(b). This abstract was inadvertently omitted. The abstract, as provided herein, presents no new matter, and the 10/16/2001 filing date should stand as the filing date. Accordingly, it is requested under 37 USC 1.115 that the abstract, as provided herein, be added as page 99 to the application.
- (X) Sequence Listing on disk.
- (X) Sequence Listing Statement.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope with sufficient postage addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit: 1/15/2002

Typed Name: Timothy H. Van Dyke

Signature 

Respectfully submitted,

By 

Timothy H. Van Dyke, Reg. No. 43218

Date: 1/15/2002

Customer No: 29847

Van Dyke & Associates, P.A.

1630 Hillcrest Street

Orlando, FL 32803

Phone: 407-228-0328; Fax: 407-228-0329

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEApplicant(s): *Graham et al.*

Application No.: 09/978,464

Filed: 10/16/2001

Group Art Unit: 1636

Title: Enhanced System for Construction of
Adenovirus Vectors

Attorney Docket No.: ADVEC101A-C1

SEQUENCE LISTING STATEMENT UNDER 37 CFR 1.8 21-825Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The information recorded in computer readable form (diskette attached) is identical to the written sequence listing for the captioned application as filed with the United States Patent and Trademark Office. Furthermore, the content of the sequence listing information recorded in computer readable form contains no new matter.

Respectfully submitted,

1-15-2002
Date
Timothy H. Van Dyke, Reg. No. 43218
Attorney for Applicants

Customer No: 29847

Van Dyke & Associates, P.A.
1630 Hillcrest Street
Orlando, Florida 32803
Phone: 407-228-0328
Fax: 407-228-0329

ABSTRACT OF THE DISCLOSURE

In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof. Use of recombinases besides Cre and recombinase recognition sites besides lox sites, and use of cells other than 293 cells are also disclosed and enabled, as are kits incorporating the site-specific vector system, as well as compositions and methods for using such compositions as vaccines or in gene therapeutic applications. Enhancement in the efficiency of site-specific recombination is provided by inclusion of a head-to-head ITR junction in each virus, plasmid, or other nucleic acid construct.

Cotransfection of 293Cre cells with pBHG10lox and a "Lox" shuttle plasmid for generation of Ad expression vectors




Fig. 1

Cotransfection of 293Cre cells with pBHG10lox and a "lox" shuttle plasmid for generation of Ad expression vectors




Fig. 2A

CONSTRUCTION OF VARIOUS SHUTTLE PLASMIDS




Fig. 2B

OLIGONUCLEOTIDES USED IN CLONING




Fig. 3

CONSTRUCTION OF A CIRCULAR GENOMIC PLASMID FOR Ad VECTOR RESCUE USING THE Cre/ loxP SYSTEM




FIG. 4A

CONSTRUCTION OF pBHGdX1Plox




Fig. 48-1

CONSTRUCTION OF pBHGdX1Plox




Fig. 4B-2

CONSTRUCTION OF pBHGE3lox




Fig. 4C

CONSTRUCTION OF Ad GENOMIC PLASMIDS ENCODING CRE




Figure 4D

CONSTRUCTION OF pΔE1SP1A & pΔE1SP1B loxP PLASMIDS FOR RESCUE OF FOREIGN DNA




Fig. 5A





Figure 5B



SEQ. ID. NO.: 12 (AB16853) and SEQ. ID. NO.: 13 (AB16854)



SEQ. ID. NO.: 14 (AB16855) and SEQ. ID. NO.: 15 (AB16856)





Figure 5D



CONSTRUCTION OF pMH4LOX, pMH4LOX Δ and pMH4LOX Δ LINK SHUTTLE PLASMIDS FOR RESCUE OF EXPRESSION CASSETTES




Fig. 6A

CONSTRUCTION OF A SHUTTLE PLASMID CONTAINING A pUC DERIVED ORIGIN




Fig. 6B

CONSTRUCTION OF HCMV loxP PLASMIDS FOR RESCUE OF EXPRESSION CASSETTES




Fig. 7

CONSTRUCTION OF pCA36LOX and pCA36LOX Δ SHUTTLE PLASMIDS FOR RESCUE OF LACZ




Fig. 8A

Cotransfection of 293Cre cells with AdLC8c DNA-TP and a shuttle plasmid containing a loxP site for generation of Ad expression vectors





Fig. 8B

Cotransfection of 293Cre cells with restricted AdLC8c DNA-TP and loxP shuttle plasmid for generation of Ad expression vectors



DEFECTIVE VIRAL VECTOR

Fig. 8C

CONSTRUCTION OF SHUTTLE PLASMIDS EXPRESSING Cre




Fig. 8D

The diagram illustrates the Cre-mediated recombination strategy for generating a defective viral vector. It begins with two plasmids: pBHG10lox (E1⁻, E3⁻, ψ⁻ Ad5) and a shuttle plasmid expressing Cre (e.g., pCA36loxΔCreT). These are cotransfected into 293 cells. The shuttle plasmid expresses Cre, which catalyzes recombination between the lox sites on the pBHG10lox plasmid, inserting foreign DNA (e.g., LacZ) into the viral genome. The resulting defective viral vector contains the insert of foreign DNA and is flanked by ITR and ψ.

Fig. 8E

CONSTRUCTION OF Ad GENOMIC PLASMID ENCODING CRE





Fig. 8F

RESCUE OF FIBRE MUTATIONS USING CRE/LOX RECOMBINATION



NONDEFECTIVE ($E1^{+}$) VIRUS WITH MUTATED FIBRE GENE

Fig. 9A



CONSTRUCTION OF pAB14lox Δ 

Fig. 9B

CONSTRUCTION OF pFG173lox



Restriction, transformation of *E. coli*,
homologous recombination




Fig. 9C

CONSTRUCTION OF pFG23dX1lox AND pFG23dX1loxc FOR RESCUE OF MUTANT FIBRE INTO AD VIRUS




Fig. 10

A PLASMID FOR RESCUE OF A FOREIGN DNA INTO AD VIRUS





Fig. 11A

RESCUE OF FIBRE MUTATIONS USING CRE/LOX RECOMBINATION



NONDEFECTIVE (E1⁺) VIRUS WITH MUTATED FIBRE GENE

FIGURE 11B

**Isolation of a virus containing a mutant fibre gene
by Cre-lox recombination using DNA-TP and cotransfection**





Fig. 12

Isolation of a virus containing a foreign DNA insert upstream of the fibre gene by Cre-lox recombination



RECOMBINANT VIRUS CONTAINING AN INSERT OF FOREIGN DNA
UPSTREAM OF THE FIBRE GENE

Fig. 13

CONSTRUCTION OF pAB14FLOX FOR ISOLATION OF AN AD VIRUS WITH A FLOXED FIBRE GENE




Fig. 14

Isolation of a virus containing a fibre gene with flanking lox P sites.




Fig.15